Ralliant (NYSE:RAL) Downgraded to Buy Rating by Wall Street Zen

Wall Street Zen lowered shares of Ralliant (NYSE:RAL) from a strong-buy rating to a buy rating in a research note published on Tuesday morning.

A number of other equities analysts also recently commented on RAL. BMO Capital Markets initiated coverage on Ralliant in a report on Monday, July 20th. They set a “market perform” rating and a $78.00 target price for the company. Barclays boosted their price objective on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price for the company. in a research report on Wednesday, May 27th. Truist Financial reaffirmed a “buy” rating and issued a $82.00 target price (up from $68.00) on shares of Ralliant in a research report on Friday, July 31st. Finally, Evercore assumed coverage on shares of Ralliant in a research note on Tuesday, June 9th. They set an “outperform” rating and a $80.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $75.70.

Ralliant Stock Performance

Shares of NYSE:RAL opened at $71.60 on Tuesday. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.75. The company has a 50-day moving average price of $67.98 and a 200-day moving average price of $55.06. The company has a market cap of $7.92 billion, a price-to-earnings ratio of -6.60, a price-to-earnings-growth ratio of 2.58 and a beta of 1.60. Ralliant has a 12 month low of $37.27 and a 12 month high of $75.41.

Ralliant (NYSE:RAL) last posted its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The company had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, equities analysts anticipate that Ralliant will post 2.87 EPS for the current year.

Ralliant Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be issued a $0.05 dividend. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s payout ratio is -1.84%.

Institutional Investors Weigh In On Ralliant

A number of institutional investors have recently made changes to their positions in the company. Cetera Investment Advisers purchased a new position in Ralliant in the 2nd quarter worth approximately $700,000. Russell Investments Group Ltd. bought a new stake in shares of Ralliant in the 2nd quarter worth $1,465,000. EverSource Wealth Advisors LLC purchased a new position in shares of Ralliant in the second quarter worth $39,000. First Trust Advisors LP purchased a new position in shares of Ralliant in the second quarter worth $2,013,000. Finally, Federated Hermes Inc. bought a new position in shares of Ralliant during the second quarter valued at $326,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.